99
Views
7
CrossRef citations to date
0
Altmetric
Device Profile

Development and performance of the zotarolimus-eluting Endeavor® coronary stent

Pages 449-459 | Published online: 09 Jan 2014
 

Abstract

Given statistically significant and clinically meaningful reductions in angiographic restenosis and repeat revascularization, treatment with drug-eluting stents (DESs) has become established as a standard of care in percutaneous coronary revascularization. However, despite their superior efficacy compared with conventional bare metal stents, experiences with first-generation DESs from both clinical trials and real-world practice have raised attention to the late safety risk of stent thrombosis that may be related to biologic incompatibility, delayed vessel healing and/or impaired endothelial function. To address the outstanding needs related to DES safety and deliverability while maintaining efficacy, the Endeavor® zotarolimus-eluting stent (Medtronic CardioVascular, CA, USA) is distinguished by favorable safety and efficacy demonstrated in clinical trials and usual practice. The purpose of this article is to describe the mechanical and pharmacologic features of the Endeavor stent, provide an overview of comparative trial results of the Endeavor stent with bare metal stents and alternative DESs, and detail recent and developing trials specific to the Endeavor stent that provide further insight to stent biocompatibility and safety.

Acknowledgements

The author expresses gratitude to Jane Moore for her editorial assistance.

Financial & competing interests disclosure

David E Kandzari receives research/grant support and consulting honoraria from Abbott Vascular, Medtronic CardioVascular and Cordis Corporation. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.